Gilead Sciences Inc
GILD
Key stats
- Open
- 171.15
- Day high
- 171.70
- Day low
- 167.93
- Previous close
- 169.73
- Volume
- 4.23M
- VWAP
- 169.36
- 52-week high
- 176.58
- 52-week low
- 116.88
- Market cap
- 210.52B
- Shares out
- 1.24B
- Employees
- 17,000
- Listed
- 1992
About Gilead Sciences Inc
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · FOSTER CITY, CA · gilead.com
Options · expiring Nov 13
Nov 12, 4:00 PM ET- Call open interest
- 1.7K
- Put open interest
- 1.7K
- Put/call
- 1.02
| Contract | Last | Traded | Volume | Open int. | IV |
|---|---|---|---|---|---|
| 162.50 put | 0.02 | Nov 12, 3:31 PM | 42 | 144 | 53.6% |
| 157.50 put | 0.18 | Nov 12, 2:21 PM | 38 | 187 | 91.2% |
| 141 call | 28.00 | Nov 12, 1:49 PM | 36 | 40 | — |
| 165 call | 3.92 | Nov 12, 3:50 PM | 33 | 178 | — |
| 134 put | 0.35 | Oct 27, 11:19 AM | 32 | 36 | 269.3% |
| 172.50 call | 0.23 | Nov 12, 3:54 PM | 29 | 133 | 39.6% |
Quarterly results
Massive · Oct 30, 2026| Q3 2026 to Sep 30, 2026 | Q2 2026 to Jun 30, 2026 | Q1 2026 to Mar 31, 2026 | Q4 2025 to Dec 31, 2025 | |
|---|---|---|---|---|
| Revenue | $8.30B | $7.80B | $6.96B | $7.92B |
| Gross profit | $6.73B | $6.22B | $5.51B | $6.30B |
| Operating income | $3.46B | −$10.39B | $2.58B | $1.98B |
| Net income | $2.43B | −$10.50B | $2.02B | $2.18B |
| Diluted EPS | 1.94 | -8.45 | 1.61 | 1.74 |
| Operating cash flow | $5.04B | $3.57B | $2.54B | $3.33B |
| Assets | $51.41B | $49.36B | $56.28B | $59.02B |
| Liabilities | $38.45B | $37.62B | $32.85B | $36.41B |
| Equity | $12.96B | $11.74B | $23.43B | $22.62B |
Technicals
Massive · Nov 12, 2026- 50-day average154.76
- 200-day average141.58
- RSI (14 days)59.3
Short interest
Massive · Oct 30, 2026- Oct 30, 202621.27M shares · 3.2 days to cover
- Oct 15, 202620.27M shares · 3.7 days to cover
- Sep 30, 202621.83M shares · 3.4 days to cover
- Sep 15, 202618.30M shares · 3.6 days to cover
Dividends
Massive · Dec 15, 2026- Ex Dec 15, 2026, paid Dec 30, 20260.8200 · 4 a year
- Ex Sep 15, 2026, paid Sep 29, 20260.8200 · 4 a year
- Ex Jun 15, 2026, paid Jun 29, 20260.8200 · 4 a year
- Ex Mar 13, 2026, paid Mar 30, 20260.8200 · 4 a year
- Ex Dec 15, 2025, paid Dec 30, 20250.7900 · 4 a year
- Ex Sep 15, 2025, paid Sep 29, 20250.7900 · 4 a year
- Ex Jun 13, 2025, paid Jun 27, 20250.7900 · 4 a year
- Ex Mar 14, 2025, paid Mar 28, 20250.7900 · 4 a year
Splits
Massive · Jan 28, 2013- Jan 28, 20132-for-1
- Jun 25, 20072-for-1
- Sep 7, 20042-for-1
Related companies
MassiveNews coverage
No stories about Gilead Sciences Inc right now.